dabigatran etexilate auxilto 150 mg hard capsules
auxilto healthcare s.r.o. bucharova 2657/12, stodulky 158 00 praha 5 , czech republic - hard capsule - dabigatran etexilate 150 mg - antithrombotic agents
dabigatran etexilate viatris 75 mg hard capsules
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - hard capsule - dabigatran etexilate 75 mg - antithrombotic agents
dabigatran etexilate viatris 150 mg hard capsules
viatris limited damastown industrial park, mulhuddart, dublin 15, dublin, ireland - hard capsule - dabigatran etexilate 150 mg - antithrombotic agents
kombiglyze xr 5/500 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 500 mg metformin hydrochloride modified release
astrazeneca pty ltd - metformin hydrochloride, quantity: 500 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; carmellose sodium; hypromellose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide yellow; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).
kombiglyze xr 5/1000 tablets 5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release
astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 5 mg - tablet, modified release - excipient ingredients: hypromellose; carmellose sodium; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).
kombiglyze xr 2.5/1000 tablets 2.5 mg saxagliptin (as hydrochloride) immediate release and 1000 mg metformin hydrochloride modified release
astrazeneca pty ltd - metformin hydrochloride, quantity: 1000 mg; saxagliptin, quantity: 2.5 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid; iron oxide yellow - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate (see clinical trials and dosing and administration for data on combinations studied).
kombiglyze xr- saxagliptin and metformin hydrochloride tablet, film coated, extended release
astrazeneca pharmaceuticals lp - saxagliptin hydrochloride (unii: z8j84yix6l) (saxagliptin anhydrous - unii:8i7io46ivq), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - saxagliptin anhydrous 2.5 mg - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate [see clinical studies (14) ]. kombiglyze xr is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. kombiglyze xr is contraindicated in patients with: limited available data with kombiglyze xr or saxagliptin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see data ]. no adverse developmental effects independent of maternal toxicity were observed when saxagliptin and metformin were administered separately or in combination to pregnant rats and rabbits during the period of organogenesis [see data ]. the estimated background risk of major birth defects is 6 to 10% in women w
dabigatran etexilate biocon 75 mg hard capsules
biocon pharma malta limited the victoria centre unit 2 lower ground floor valletta road mosta mst 9012 , malta - hard capsule - dabigatran etexilate 75 mg - antithrombotic agents
dabigatran etexilate biocon 110 mg hard capsules
biocon pharma malta limited the victoria centre unit 2 lower ground floor valletta road mosta mst 9012 , malta - hard capsule - dabigatran etexilate 110 mg - antithrombotic agents
dabigatran etexilate biocon 150 mg hard capsules
biocon pharma malta limited the victoria centre unit 2 lower ground floor valletta road mosta mst 9012 , malta - hard capsule - dabigatran etexilate 150 mg - antithrombotic agents